1310 Chesapeake Terrace
375 articles with Accuray Inc.
Accuray Inc. (NASDAQ: ARAY) today reported its financial results for the second quarter of fiscal 2019 ended December 31, 2018.
The Urology Group Surpasses 1,600 Prostate Cancer Patients Treated with the Accuray CyberKnife® M6™ System
According to the American Cancer Society, prostate cancer is the most common cancer in American men other than skin cancer.
Management will host a conference call to review the results at 1:30 p.m. PT/4:30 p.m. ET on the same day.
Accuray Incorporated announced today that the Company will present at the J.P. Morgan 37th Annual Healthcare Conference on Wednesday, January 9, 2019 at the Westin St. Francis Hotel in San Francisco. Attendance at the conference is by invitation only.
Accuray Incorporated (NASDAQ: ARAY) announced today that its Board of Directors has named Shig Hamamatsu as senior vice president, chief financial officer effective immediately.
Accuray Showcases Radiation Therapy Innovations Designed to Improve What's Possible for Patients at ASTRO 2018
Meeting attendees can visit Accuray at booth #2511 on October 21 - 23, 2018 in San Antonio, Texas
Management will host a conference call to review the first quarter results at 1:30 p.m. PT/4:30 p.m. ET on October 30, 2018.
Technische Universität München Hospital is First in Germany to Treat Cancer Patients with Accuray Radixact® System
Versatile, Easy-to-Use System Offers Patients Access to Technologically Advanced Cancer Care
Adoption of Innovative Radiation Therapy Technology Reinforces South Asian Cancer Center's Position as Pioneer in Patient Care
Internationally Renowned Centre in Cambridge, England is First NHS Hospital to Install the Innovative Radiation Therapy System
Accuray Incorporated will report results for its fourth quarter and fiscal year 2018 ended June 30, 2018 on Thursday, August 16, 2018 after the market close.
Accuray Inc.(NASDAQ: ARAY) announced today the appointment of Joseph E. Whitters to the company's Board of Directors, effective as of July 16, 2018. In addition, he will serve on the Board's Audit Committee. With Mr. Whitters' appointment, the Accuray Board has been expanded to eight members.
The Accuray CyberKnife® System empowers clinicians to make the most of their skills in treating cancer.
New Studies Show the Accuray TomoTherapy® System Provides Greater Precision, Excellent Clinical Outcomes in Patients Undergoing Total Body Irradiation
Accuray Incorporated (NASDAQ: ARAY) announced today that recently published data from two new studies demonstrate the benefits of the TomoTherapy® System in the delivery of total body irradiation (TBI), a procedure commonly used to prepare patients being treated for leukemia and multiple myeloma for a bone marrow transplant. TBI involves irradiation of the entire body, elevating the need for precision, accuracy and homogeneity in radiation dose delivery
Accuray Unveils New Company Website Reflecting Industry-Leading Patient-First Cancer Treatment Innovation and Care
Check out the new site at www.accuray.com.
Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third fiscal quarter ended March 31, 2018.
Innovative Radiation Therapy Device Enables Cancer Center to Provide Faster, Extremely Precise Radiation Treatments
Erasmus MC Completes First Step in the Evolution of Online Adaptive Radiation Therapy with the CyberKnife® System
New Clinical Trial Evaluates Use of Online-Adaptive Stereotactic Body Radiation Therapy Approach in the Treatment of Oligometastases
Accuray announced today it has retired all February 2018 convertible notes, including $13M aggregate principal amount of its 3.50% convertible senior notes and $27M aggregate principal amount of its 3.50% Series A convertible senior notes both due February 1, 2018.
1/29/2018The study is the largest single-center study of TN patients treated with the CyberKnife technology reported to date.